Posted 22 February 2021 AM
The new time limit on taking up positive PBAC recommendations announced last week looms over a number of drugs presently stalled in the post-PBAC phase.
Under the new limit, the reimbursement committee will review positive recommendations "not accepted" by sponsors within two years. Sponsors will be forced to either confirm they have chosen not to proceed with the listing process (in which case the recommendation will be ceased) or request that the recommendation be retained, say why and give a date for when they intend to proceed with listing.